ARS Pharmaceuticals Inc (SPRY)

Currency in USD
17.75
-0.60(-3.27%)
Closed·
After Hours
17.79+0.04(+0.23%)
·

SPRY Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.35 / -0.34
Revenue / Forecast
7.97M / 7.48M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
06/2025--/-0.459--/13.77M----Free Sign Up
03/2025-0.35/-0.347.97M/7.48M-2.94%+6.55%Free Sign Up
12/20240.48/-0.1386.6M/5.1M+469.23%+1,598.04%Free Sign Up
09/2024-0.2/-0.1432.07M/575K-40.35%+260%Free Sign Up
06/2024-0.13/-0.12500K/1M-8.33%-50%Free Sign Up
03/2024-0.11/-0.11--/--0%--Free Sign Up
12/2023-0.07/-0.07--/--0%--Free Sign Up
09/2023-0.16/-0.18--/666.67K+11.11%-100%Free Sign Up
06/2023-0.18/-0.1810K/10K0%0%Free Sign Up
03/2023-0.16/-0.1620K/20K0%0%Free Sign Up

All numbers in USD

ARS Pharmaceuticals Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue of $8M beats forecast, driven by successful NEFI launch; net loss of $33.9M or $0.35 per share
  • Stock falls 3.67% premarket despite revenue beat; market cap at $1.31B with strong financial health score of 3.27
  • Company projects $210-220M operating expenses for 2025; anticipates sales inflection in Q3 with peak in Aug-Sep
  • NEFI gains traction with 13,000 prescriptions; company aims to cover 80% of commercial lives by Q3
  • International launches planned from mid-2025 to early 2026; new DTC campaign 'Hello NEFI, Goodbye Needles' launched
Last Updated: 14/05/2025, 14:20
Read Full Transcript

FAQ

What Is ARS Pharmaceuticals's Earnings Per Share (TTM)?

The ARS Pharmaceuticals EPS (TTM) is -0.16.

When Is The Next ARS Pharmaceuticals Earnings Date?

ARS Pharmaceuticals will release its next earnings report on 05 Aug 2025.

What Is ARS Pharmaceuticals’s Revenue Forecasts For Upcoming Quarters?

ARS Pharmaceuticals’s revenue forecast is 13.77M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.